BofA analyst Tazeen Ahmad raised the firm’s price target on Pharvaris to $11 from $8 and keeps an Underperform rating on the shares after the company announced the Phase 2 CHAPTER-1 trial evaluating deucrictibant as a prophylactic treatment for HAE achieved its primary endpoint. While “encouraged” by the positive data, which “provides some validation for deucrictibant’s clinical activity as a prophylactic treatment,” the firm continues to look for color on some key aspects and highlights that the prophylactic HAE program remains on clinical hold in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHVS:
- Pharvaris 11.125M share Secondary priced at $24.00
- Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
- Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Pharvaris announces ‘positive’ data from CHAPTER-1 study of deucrictibant
- Pharvaris to Present at the GA²LEN UCARE Conference 2023